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AF, whereas dual antiplatelet therapy prevents major adverse cardiovascular events, including stent thrombosis after 
PCI. A typical triple antithrombotic therapy, involving an anticoagulant, i.e. vitamin K antagonist (VKA), together with 
aspirin and P2Y12 inhibitor, usually clopidogrel, has been shown to minimize ischemic and stroke risks, but is associated 
with increased risk of major bleeding. The use of dabigatran, rivaroxaban, or apixaban in combination with antiplatelet 
agents lowers the risk of major bleeding and makes it an option preferred over triple therapy in the majority of PCI 
patients with AF. The consistency across randomized controlled trials on combination therapy with non-vitamin K anta-
gonist oral anticoagulant (NOAC) and clopidogrel, including patients with acute coronary syndromes, led to changes in 
everyday practice. However, the use of triple and dual antithrombotic therapy at high bleeding risk should be individua-
undergoing PCI in the era of NOAC.
 
non-vitamin K antagonist oral anticoagulant
patients will require percutaneous coronary intervention 
with stent implantation (PCI) during their lifetime (1). The 
most frequent indication for double or triple antithrombotic 
therapy (DAT, TAT), including a P2Y12 inhibitor with or with-
out aspirin and an oral anticoagulant (OAC), is an acute 
coronary syndrome (ACS) with concomitant AF, mechani-
cal heart valves, left ventricular thrombus, or recent ve-
nous thromboembolism (2). Decision making on the length 
and intensity of antithrombotic therapy in patients with AF 
and PCI is based on the predicted risk of thromboembo-
lism and bleeding. Traditionally TAT involving vitamin K 
antagonist (VKA), mostly warfarin, aspirin and clopidogrel 
was administered for 6–12 months to reduce the risk of 
stroke (with VKA) and coronary thrombotic events (with 
antiplatelet drugs) (3). Available data clearly showed that 
TAT is associated with a very high risk of bleeding com-
pared with DAT therapy reduced to an oral anticoagulant 
and a single antiplatelet agent. The 30-day bleeding rates 
in patients with TAT, including VKA, reaches 2.2%, grow-
ing to 12% in one-year follow-up (4), worsening prognosis. 
Major bleeding in patients with ACS is associated with a 
randomized controlled trials (RCTs) providing direct com-
parisons between diverse DAT and TAT regimens suggest 
the superiority of DAT after an initial short-period treat-
ment with TAT for the majority of patients with AF under-
going PCI (6–9).
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Oral anticoagulants in atrial fibrillation
OAC in AF patients reduces the risk of stroke and sy-
stemic thromboembolism (SE) by more than 60% de-
monstrating superiority over aspirin monotherapy or 
clopidogrel-based dual antiplatelet therapy (DAPT) 
(10). Non-vitamin K antagonist oral anticoagulants 
(NOAC) including apixaban, edoxaban, dabigatran and 
rivaroxaban, are recommended in preference to VKAs 
in patients with nonvalvular AF. In a meta-analysis of 
seminal phase 3 AF RCTs, NOACs reduced all-cause 
mortality, the risk of stroke or SE and intracranial ble-
eding by 10, 19% and 52% respectively, but increased 
gastrointestinal (GI) bleeding risk by one quarter com-
pared with warfarin (11). An increase in GI bleeds on 
NOACs was driven mainly by results of seminal RCTs 
evaluating dabigatran and rivaroxaban. Nevertheless, 
reduction in bleeding-related mortality (relative risk, 
RR: 0.54, 95%; CI: 0.44–0.67) for all NOACs as com-
pared with warfarin has been demonstrated (12).
Dual antiplatelet therapy after PCI
There is consensus on a 6-month DAPT after PCI 
for stable angina. A shorter (1-3 months) duration of 
DAPT should be considered in patients at high blee-
ding and low ST risk. In patients after ACS, European 
Society of Cardiology (ESC) guidelines recommend de-
fault 12-month DAPT and shorter its duration may be 
considered among those at high bleeding risk (13, 14. 
High-risk features for ST that may be precipitated by 
too early discontinuation of DAPT, include stenting of 
the left main artery, or proximal left anterior descending 
artery or last remaining patent artery, suboptimal stent 
deployment, large stent length (>60 mm), PCI of the bi-
furcation with two stents implanted, treatment of chro-
nic total occlusion and previous ST, diabetes mellitus 
and chronic kidney disease (2, 15). Prolonging DAPT 
duration may substantially reduce the risk of ischemic 
events in high-risk populations. It has been found that 
the therapy with clopidogrel, ticagrelor or prasugrel ex-
tended beyond 12 months is associated with reduced 
ischemic events and ST but increased bleeding comp-
lications with no change in the mortality rate. The grea-
test benefit of long-term DAPT with ticagrelor 60 mg 
b.i.d. has been observed in high-risk post-myocardial 
infarction (MI) patients with diabetes, multivessel coro-
nary artery disease, and peripheral artery disease (16).
Randomized trials on combination  
anticoagulant and antiplatelet therapy
Several RCTs have compared TAT with DAT in AF pati-
ents undergoing coronary stenting. Early moderate-si-
ze studies focused on the efficacy and safety of shor-
tening VKA-based TAT, with the largest impact of the 
WOEST and ISAR-TRIPLE trials.
The WOEST trial (What is the Optimal antiplatElet and 
anticoagulant therapy in patients with oral anticoagu-
lation and coronary StenTing) compared TAT (VKA + 
clopidogrel + ASA) with DAT (VKA + clopidogrel) in 
patients undergoing PCI who required OAC due to AF, 
mechanical heart valve and other reasons, e.g. apical 
aneurysm, pulmonary embolism, peripheral artery di-
sease. Bleeding episodes were almost 3-fold lower in 
the DAT group (hazard ratio, HR: 0.36, 95% CI: 0.26–
0.50). In the WOEST trial, only 69% of patients in the 
TAT group had AF, and 69% of participants in this study 
used a 12-month TAT compared with other studies (4).
The ISAR-TRIPLE trial (Triple Therapy in Patients on 
Oral Anticoagulation After Drug Eluting Stent Implanta-
tion) evaluated shorten the duration of clopidogrel ther-
apy from 6 months to 6 weeks in 614 patients receiving 
VKA who underwent PCI (one-third with ACS). The pri-
mary composite end-point of death, MI, ST, ischemic 
stroke or Thrombolysis in Myocardial Infarction (TIMI) 
major bleeding at 9 months, did not differ between the 
6-week and 6-month (HR: 1.14, 95% CI: 0.68–1.91) 
(17). Although WOEST and ISAR-TRIPLE studies were 
underpowered, shortening of TAT emerged as a safe 
option in patients with AF and ACS and/or an elective 
PCI. Based on results of the WOEST and ISAR-TRIP-
LE studies, the 2015 ESC guidelines for the manage-
ment of ACS in patients presenting without persistent 
ST-segment elevation recommended shortening TAT 
duration in patients at high bleeding risk to one month, 
irrespective of the stent type (13).
The introduction of the NOACs has added to the comp-
lexity of treatment decisions in AF patients, but showed 
new opportunities increasing the safety of anticoagu-
lant patients. Until now, 4 large RCTs compared the 
risk-to-benefit ratio of warfarin and the NOACs in com-
bination with antiplatelets .
The PIONEER AF-PCI trial (an open-label, randomi-
zed, controlled, multicenter study exploring two treat-
ment strategies of rivaroxaban and a dose-adjusted 
oral vitamin K antagonist treatment strategy in subjects 
with atrial fibrillation who undergo percutaneous coro-
nary intervention) tested two lower rivaroxaban doses 
(15 mg o.d. plus P2Y12 inhibitor for 12 months and 2.5 
mg b.i.d. plus DAPT for 1, 6, or 12 months) versus VKA 
plus DAPT for 1, 6, or 12 months. The TIMI major ble-
eding was lower in the two groups receiving rivaroxa-
ban (HR: 0.59, 95% CI: 0.47–0.76; HR 0.63, 95% CI: 
0.50–0.80; respectively) compared with the TAT group. 
There was no difference in all-cause death, death from 
cardiovascular causes, MI, or stroke between the three 
groups (7).
The REDUAL-PCI trial (A Prospective Randomised, 
Open Label, Blinded Endpoint Study to Evaluate DUAL 
Antithrombotic Therapy With Dabigatran Etexilate (110 mg 
and 150 mg b.i.d.) Plus Clopidogrel or Ticagrelor vs. 
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Triple Therapy Strategy With Warfarin (INR 2.0 – 3.0) 
Plus Clopidogrel or Ticagrelor and Aspirin in Patients 
With Non Valvular Atrial Fibrillation That Have Under-
gone a Percutaneous Coronary Intervention With Sten-
ting) which assessed DAT (dabigatran 110 mg bid or 
150 mg bid and a P2Y12 inhibitor, mostly clopidogrel) 
with TAT (warfarin and clopidogrel and ASA), showed 
a reduction of major and non-major bleeding events in 
the DAT group with 110 mg dabigatran (HR: 0.52, 95% 
CI: 0.42–0.63) and the DAT group with 150 mg dabigat-
ran (HR: 0.72, 95% CI: 0.58–0.88) compared with TAT. 
There was no difference in ischemic complications and 
death between DAT and TAT strategy (8).
The AUGUSTUS trial (An Open-label, 2×2 Factorial, 
Randomized Controlled, Clinical Trial to Evaluate the 
Safety of Apixaban vs. Vitamin K Antagonist and Aspi-
rin vs. Aspirin Placebo in Patients With Atrial Fibrillation 
and Acute Coronary Syndrome or Percutaneous Coro-
nary Intervention),the largest trial to date on combined 
antithrombotic therapy in AF patients undergoing PCI, 
showed that apixaban 5 mg b.i.d. reduces the risk of 
major bleeding or clinically relevant non-major (CRNM) 
bleeding compared with VKA (HR: 0.69, 95% CI: 0.58–
0.81). Of note, aspirin compared with placebo was as-
sociated with higher bleeding risk (HR: 1.89, 95% CI: 
1.59–2.24). The safest combination therapy apixaban 
with P2Y12 involving inhibitor (predominantly clopidog-
rel) with 16.8 bleeding events /100 patients-years ob-
served vs 49.1 events /100 patients-years in the group 
with VKA + aspirin + P2Y12 inhibitor (9).
The ENTRUST-AF PCI trial (Evaluation of the safety 
and efficacy of an edoxaban-based compared to a vi-
tamin K antagonist-based antithrombotic regimen in 
subjects with atrial fibrillation following successful per-
cutaneous coronary intervention (PCI) with stent place-
ment, n=1506) demonstrated edoxaban 60 mg o.d. + 
P2Y12 inhibitor for 12 months to be non-inferior to VKA 
+ P2Y12 inhibitor + aspirin (100 mg once daily, for 1–12 
months) regarding major or CRNM bleeding events (HR 
0.83, 95% CI 0.65–1.05) (6).





AUGUSTUS (n=4614) ENTRUST-AF PCI 
(n=1506)
Study year 2016 2017 2019 2019
Time science index 
event 72 hours 120 hours 14 days 5 days
Treatment strategies • Rivaroxaban 15 mg/d + 
a P2Y12 inhibitor  
• Rivaroxaban 2.5 mg 
b.i.d + DAPT • VKA + 
DAPT
• Dabigatran 110 mg 
b.i.d + a P2Y12 inhibitor  
• Dabigatran 150 mg 
b.i.d + a P2Y12 inhibitor  
• VKA + DAPT
• Apixaban 5 mg bid+ DAPT 
• Apixaban 5 mg b.i.d + a 
P2Y12 inhibitor  
• VKA + DAPT  
• VKA + a P2Y12 inhibitor
• Edoxaban 60 mg/d 
+ a P2Y12 inhibitor • 
VKA + DAPT
Clinical setting
Elective PCI 61.5% 49.5% 38.8% 48.0%
Primary PCI 38.5% 50.5% 37.3% 52.0%
Medically managed 
ACS
0.0% 0.0% 23.9% 0.0%
P2Y12 inhibitor
Clopidogrel 94.4% 87.9% 92.6% 92.0%
Ticagrelor 4.3% 12.1% 6.2% 7.0%
Prasugrel 1.3% 0.0% 1.2% 0.5%
TAT regimen duration 
(months) 1.6 or 12 1 (BMS) or 3 (DES) 6 1–12
Follow up  (months) 12 14 6 12
Safety end-point A composite of TIMI 
major bleeding or minor 
bleeding
Major or CRNM ISTH 
bleeding
Major or CRNM ISTH 
bleeding
Major or CRNM ISTH 
bleeding
A composite of CV 
death, MI or stroke, and 
ST
A composite of all-cause 
death or ischemic event 
(including stroke, MI, 
ST, SE, or unplanned 
revascularization)
A composite of all-cause 
death or ischemic event 
(including stroke, MI, ST 
revascularization)
A composite of CV 
death or ischemic 
event (including stro-
SE)
triple antithrombotic therapy; BMS, bare-metal stent; DES, drug-eluting stent; OAC, oral anticoagulation; TIMI, Thrombolysis in Myocardial Infarction; CRNM, 
clinically relevant non-major; ISTH, International Society on Thrombosis and Haemostasis; MACE, major adverse cardiac events; MI, myocardial infarction; 
CV, cardiovascular; SE, systemic embolism; ST, stent thrombosis.
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There is strong evidence from several meta-analyses 
that in patients with AF undergoing PCI, antithrombo-
tic regimens involving a VKA with DAPT should be ge-
nerally avoided, whereas the use of a NOAC with a 
P2Y12 inhibitor without aspirin remains the best option 
19).
In the most recent systematic review of five RCTs for 
patients with AF undergoing PCI (WOEST, PIONEER 
AF-PCI, RE-DUAL PCI, AUGUSTUS, ENTRUST-AF 
PCI, n=11,542) a lower bleeding risk, without a re-
duction in antithrombotic effectiveness was obser-
ved for regimens in which aspirin was discontinued 
(20). TIMI major bleeding was lower for NOAC plus 
P2Y12 inhibitor (RR: 0.52, 95% CI: 0.35–0.79) and 
VKA plus P2Y12 inhibitor (RR: 0.57, 95% CI: 0.31–
1.00), with no difference for NOAC plus DAPT (RR: 
0.69, 95% CI: 0.40–1.16) as compared with VKA plus 
DAPT. Major adverse cardiovascular events, inclu-
ding MI and ST, did not differ between DAT, NOAC 
plus DAPT and VKA plus DAPT regimen as a refe-
rence .
Controversial issues regarding TAT
Findings across studies on DAT and TAT in patients 
with AF and PCI may be affected by different regimens 
of NOACs, and P2Y12 inhibitors, different doses of NO-
ACs and open-label trial design. Seminal trials were 
largely underpowered for differences in rare events as 
the incidence of MI, ST, and ischemic stroke. Moreover, 
major adverse cardiac events (MACE) definition varied 
among studies. A composite end-point included MI, ST, 
and stroke in all 4 studies, all-cause death (RE-DUAL 
PCI, AUGUSTUS), cardiovascular death (PIONEER-AF 
PCI and ENTRUST-AF PCI) urgent/unplanned revas-
cularization in the RE-DUAL PCI and AUGUSTUS tri-
als. However, as for the ischemic events, there was 
a clear trend towards a higher number of  MI and ST 
with DAT vs. TAT in all 4 trials, and some meta-analy-
ses showed statistically significantly higher rates of MI 
and/or ST with DAT vs. TAT (21, 22). This observation 
was mainly driven by studies with reduced dose NO-
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FIGURE 1. Safety and efficacy of different anticoagulant regimens in patients with atrial fibrillation and coronary artery disease. 
Major bleeding TIMI (Thrombolysis in Myocardial Infarction) – PANEL A, intracranial bleeding – PANEL B, myocardial infarction 
– PANEL C, major adverse cardiovascular events – PANEL D, stent thrombosis – PANEL E. VKA, Vitamin K antagonist; DAPT, 
dual antiplatelet therapy; P2Y12 inhibitor plus aspirin; OR, the odds ratios. Based on Lopes et al. (20)
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ta-analysis suggested that the likelihood of an excess 
of thromboembolic events during DAT vs. TAT was low 
(23). Lower bleeding risk with DAT compared with TAT 
was seen regardless of the used bleeding scale, i.e., 
TIMI bleeding scale in the PIONIER – AF trial versus 
International Society on Thrombosis and Haemostasis 
(ISTH) bleeding classifications in other studies.
Optimal TAT duration before DAT and timing of aspi-
rin cessation post an ACS or elective PCI remain unk-
nown. Seminal trials on a combination of anti thrombotic 
agents in patients with AF undergoing PCI have inclu-
ded a large proportion of patients with ACS (38.8–
61.5%) who have higher ST risk compared with tho-
se undergoing elective PCI. A peri-procedural period 
of TAT was ranging from 3 days (PIONIER-AF) to 14 
days after PCI (AUGUSTUS). Half of the patients in TAT 
groups of the PIONEER AF-PCI trial continued DAPT 
for 12 months without a difference in major bleeding 
or transfusion rates between the NOAC + DAPT and 
VKA + DAPT groups (15).
The optimal P2Y12 inhibitor in ACS or elective PCI in 
combined therapy remains to be established. Most stu-
dies on DAT and TAT were conducted with clopidogrel, 
supporting its use in combination therapy. In contrast, 
there is currently limited evidence to support the use 
of OACs with ticagrelor or prasugrel in DAT after PCI 
as an alternative to TAT. The routine use of ticagrelor 
or prasugrel in TAT is contraindicated, however, based 
mainly on the results of the RE-DUAL-AF where 12% 
of patients were treated with ticagrelor (n=327), the 
2019 ESC guidelines on chronic coronary syndromes 
recommended DAT with ticagrelor or prasugrel in pa-
tients with a moderate-to-high risk of ST (Class IIb, le-
vel of evidence C, ) (2). The North American 
consensus statement on antithrombotic therapy in pati-
ents with AF undergoing PCI makes DAT with ticagrel-
or but not prasugrel as an option for patients with high 
ischemic and low bleeding risk (24). Other strategies 
to decrease bleeding risk during DAT and TAT include 
adding a proton pump inhibitor and avoiding nonsteroi-
dal anti-inflammatory agents; however, these strategies 
were not tested in RCTs.
Real-life evidence
Observational studies on antithrombotic therapy fol-
lowing PCI in anticoagulated AF patients largely re-
ported findings similar to RCTs. Sindet-Pedersen et al. 
(25), based on the Danish nationwide registry (n=3222), 
showed for 3- and 12-month TAT with NOAC, a 1.94% 
and 4.50% decrease in absolute major bleeding risk 
and similar thromboembolic protection, as compared 
with TAT with VKA. Of note, DAT with NOAC, when 
compared with DAT with VKA, resulted in lower abso-
lute risk of MI (–1.53% and –2.99% at 3 and 12 months, 
respectively) with no significant difference in major ble-
eding, stroke and all-cause mortality. In 2015 a Europe-
an Heart Rhythm Association Survey showed that most 
centers preferred VKA over NOACs in TAT after PCI 
in AF patients with 12% preferring NOAC. Over 70% 
of centers used TAT therapy with aspirin (75–100 mg/
day) and clopidogrel (75 mg/day) for 3 months followed 
by 3-6 months of DAT in patients with a DES and AF. 
Table 2. Recommendations of the European Society of Cardiology for combined antiplatelet and antithrombotic therapy in AF 
patients undergoing PCI (2) 
Recommendations Class* Level**
should be considered if the risk of stent thrombosis is low or if concerns about bleeding risk prevail over 
concerns about the risk of stent thrombosis, irrespective of the type of stent used.
IIa B
of stent thrombosis outweighs the bleeding risk. TAT total duration (<6 months) depends on the assess-
ment of thrombotic/bleeding risk. 
IIa C
DAT with an OAC and either ticagrelor or prasugrel as an alternative to TAT (OAC + aspirin + clopidog-
rel) may be considered in patients with a moderate-to-high risk of stent thrombosis, irrespective of the 
type of stent used. 
IIb C
The use of prasugrel/ticagrelor as part of TAT with aspirin and an OAC is contraindicated. III C
A full dose NOAC (apixaban 5 mg b.i.d., dabigatran 150 mg b.i.d., edoxaban 60 mg o.d., or rivaroxaban 
20 mg o.d.) is recommended as preferred over VKA in combination therapy with antiplatelet drugs. I A
When concerns about high bleeding risk prevail over concerns about stent thrombosis or ischemic stro-
ke, reduced NOAC dose (rivaroxaban 15 mg o.d, dabigatran 110 mg b.i.d) should be considered for DAT 
and TAT.
IIa B
In patients treated with VKA in combination therapy with antiplatelets, a target international normalized 
ratio should be in the range of 2.0 - 2.5 and time in the therapeutic range should exceed 70%. IIa B
The use of a proton pump inhibitor is recommended in patients at high risk of gastrointestinal bleeding 
receiving aspirin monotherapy, DAPT, or OAC monotherapy. I A
*Class of recommendation, ** Level of evidence 
For abbreviations see Table 1; DAT double antithrombotic therapy, NOAC, non-vitamin K antagonist oral anticoagulant
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Nearly half of the centers considered bare-metal stents 
in case of MI in the group at high bleeding risk and 
two-thirds in elective PCI (26).
 
There are limited data on the combined antiplatelet and 
anticoagulant therapy safety, in particular, AF patient 
subsets, including the elderly, underweight or obesity, 
patients with cancer, chronic kidney disease, liver inju-
ry, thrombocytopenia, and ST (1, 3).
The greater risk of bleeding in older patients with AF 
makes combined antithrombotic therapy challenging. It 
appears that in the group above 75 years, similar to the 
younger subjects, NOAC reduced risk of ICB but inc-
reased GI bleeds compared with VKA (11). In RCTs, 
apixaban was the only NOAC that showed a reducti-
on of major bleeding among older patients compared 
with VKA (27). Four large RCTs comparing warfarin 
and the NOACs in combination with antiplatelets, sho-
wed a significant reduction of 35% in major bleeding for 
DAT (28). The mean age of study participants was 69.9 
and 70.8 years, while the elderly constituted 22.9% and 
34% (RE-DUAL PCI trial and PIONEER AF-PCI stu-
dy, respectively) (7, 8). In the Spanish study on patients 
-
pared with DAPT, was associated with a lower rate of 
thromboembolism (0.6% vs. 6.9%) and a higher rate of 
major bleeding (11.7% vs. 2.4%, respectively) (28).
The bleeding risk of antiplatelets, particularly prasug-
rel, was markedly increased in underweight patients 
(13). Low body weight may increase NOAC exposure 
and increase the risk of bleeding (29). Post hoc ana-
lyses of RCTs showed similar efficacy and safety of 
dabigatran in patients with body weight below 50 kg, 
whereas observational studies suggested higher blee-
-
is a dose-reduction criterion, was safer than warfarin in 
the underweight patients (30). To our knowledge, there 
have been no outcome data for rivaroxaban use in pati-
ents <60 kg published to data. 
Obesity may enhance platelet reactivity, diminishing 
effect of antiplatelet drugs, as observed in ex-vivo as-
says; however, there have been no trials on dosing re-
gimens and long-term outcomes regarding body mass 
index (BMI). Studies on NOAC reported little or no chan-
ges in the volume of distribution and half-life in obese 
patients, although they did not include patients with 
2 treated 
with rivaroxaban had a reduced stroke risk compared 
with the rest of the cohort, and a similar trend was ob-
2 
(31). Considering limited data on NOAC use in patients 
m2), VKA might be considered the first option of treat-
ment. NOAC plasma level measurement and dosage 
modification under the guidance of a hematologist for 
patients with extremely low and high body weight may 
be another option, although this approach has not been 
tested in long-term clinical studies (32). DAT and TAT 
should be individualized in this population due to limited 
data on combined therapy.
Chronic kidney disease
Chronic kidney disease (CKD) is characterized by an 
increased risk of thromboembolism and bleeding. The 
renal elimination varies between NOACs, with the lo-
west values for edoxaban and apixaban (27% and 35%, 
respectively). Apixaban, edoxaban and rivaroxaban are 
approved in Europe in patients with CKD and creatinine 
clearance (CrCl) of 15–29 mL/min in a reduced dose 
and contraindicated if CrCl is below 15 mL/min. In the 
retrospective analysis of RCTs comparing NOACs with 
VKA in AF patients, the efficacy and safety of NOACs 
were consistent across subgroups with mild to modera-
te CKD and without CKD (33). The bleeding benefit of 
NOAC over warfarin was observed for apixaban but not 
for dabigatran at lower CrCl values (27).
However, the landmark NOAC trials in AF patients un-
dergoing PCI excluded patients with severe renal im-
pairment (CrCl of <30 mL/min) and did not focus on other 
subgroups with CKD. In the PIONEER AF-PCI trial 
27.9% of patients had CrCl of 30 to 60 ml/min and 0.8% 
had CrCl <30 mL/min (7). The AUGUSTUS trial inclu-
ded 8.4% patients with creatinine >1.5 mg/dL (9). Both 
studies showed the superiority of DAT in the reducti-
on of bleeding complications and the same efficacy 
in thromboembolism prevention; however, the impact 
of kidney function on results was not analyzed. As the 
antiplatelet efficacy of aspirin is lower than clopidogrel, 
and its use in DAT and TAT increases major bleeding 
risk, clopidogrel should be administered as the single 
agent in combined antithrombotic therapy in patients 
with advanced CKD (34). DAT should be considered as 
an alternative in patients with mild-to-moderate CKD. 
Cancer
It is estimated that 5% of patients have or develop AF 
within the first months after diagnosis of cancer (35). 
Thromboembolic risk is increased in various types of 
cancer, with the greatest elevation in the pancreas, 
ovary, brain and lung cancers, and hematological 
neoplasms. Specific factors such as thrombocytopenia, 
neoplastic infiltration of arterial vessels, metastases, 
radiation therapy increase bleeding risk in cancer (36). 
AF patients with cancer belong to the group with very 
high bleeding risk, where TAT after PCI is rarely ins-
tituted, except subjects long-term after a few years of 
treatment, with good prognosis and without thrombocy-
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topenia (37). Most centers, especially in the first weeks 
of cancer diagnosis, prefer DAT, i.e. clopidogrel with 
low-molecular-weight heparin or VKA. The duration of 
DAT is up to 12 months depending on the oncological 
status, thromboembolic and bleeding complications 
during therapy, and may be shortened to 1-6 months 
in the case of unacceptable bleeding (36). The 2019 
ISTH guidelines on anticoagulation in patients with AF 
and cancer receiving chemotherapy recommend indi-
vidualized anticoagulation, based on thrombotic/ble-
eding risk and patient preferences. The preference of 
NOACs over VKAs or heparins is suggested in patients 
with newly diagnosed AF, except for subjects with ac-
tive duodenal ulcer, gastritis, esophagitis, colitis or with 
luminal GI cancer and an intact tumor (38).
Thrombocytopenia
Up to 3% of AF patients have thrombocytopenia defined 
as a platelet count below 100,000/μL (39). The PIONE-
ER AF-PCI, RE-DUAL PCI and AUGUSTUS trial ex-
cluded patients with a platelet count below 90,000-
100,000/μL, while ENTRUST-AF PCI excluded patients 
with severe thrombocytopenia (< 50,000/μL) (6–9). The 
current ESC guidelines do not provide any recommen-
dations for the use of DAT and TAT in thrombocytopenic 
patients (2, 3). In recent studies, VKA in patients with 
moderate thrombocytopenia increased 3-fold the risk 
of minor bleedings (40). NOAC at reduced dose had 
acceptable safety and effectiveness in patients with a 
mean platelet count of 78,000 /μL (41). McCarthy et al. 
based on two RCTs with second-generation drug-elu-
ting stents, where a subgroup of patients with moderate 
thrombocytopenia was enrolled, recommended shor-
tening DAPT to one month after ACS, avoiding ticag-
relor and prasugrel and avoiding TAT in subjects with 
indication to OAC (39). In patients with AF and platelet 
count <50,000/μL, the anticoagulation should be indi-
vidualized given no evidence from randomized trials. 
Clopidogrel should be preferred in patients with severe 
thrombocytopenia.
The dual-therapy approach in AF patients undergoing 
PCI is now supported by current American and Europe-
an guidelines. Summary of the current recommenda-
tions has been shown in  and 3.
Conclusions
Overall, dual antithrombotic therapy with NOAC and 
P2Y12 inhibitor (predominantly clopidogrel) is superior 
to triple therapy (VKA/NOAC + DAPT) in most patients 
with AF, as shown in RCTs. The excessive bleeding risk 
prevails benefit in reducing stent thrombosis. Current 
data suggest that a short course of TAT (e.g., 1 week) 
should be a default therapy for the majority of patients, 
followed by DAT for up to 12 months, and then with OAC 
only. Selected patients at high ischemic risk may be-
nefit from a longer course of TAT. The duration of DAT 
and TAT can be modified based on a clinical setting 
(elective PCI vs ACS) and individual patient’s ischemic 
and bleeding risks. Individualized therapy in ACS and 
PCI patients who required anticoagulation should be 
considered in the presence of extreme ischemic or ble-
eding risks.
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